nirmatrelvir and Disease-Models--Animal

nirmatrelvir has been researched along with Disease-Models--Animal* in 2 studies

Other Studies

2 other study(ies) available for nirmatrelvir and Disease-Models--Animal

Article	Year
The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern. Nature communications, 2022, 02-15, Volume: 13, Issue:1 There is an urgent need for potent and selective antivirals against SARS-CoV-2. Pfizer developed PF-07321332 (PF-332), a potent inhibitor of the viral main protease (Mpro, 3CLpro) that can be dosed orally and that is in clinical development. We here report that PF-332 exerts equipotent in vitro activity against the four SARS-CoV-2 variants of concerns (VoC) and that it can completely arrest replication of the alpha variant in primary human airway epithelial cells grown at the air-liquid interface. Treatment of Syrian Golden hamsters with PF-332 (250 mg/kg, twice daily) completely protected the animals against intranasal infection with the beta (B.1.351) and delta (B.1.617.2) SARS-CoV-2 variants. Moreover, treatment of SARS-CoV-2 (B.1.617.2) infected animals with PF-332 completely prevented transmission to untreated co-housed sentinels. Topics: A549 Cells; Administration, Oral; Animals; Chlorocebus aethiops; Coronavirus 3C Proteases; COVID-19; COVID-19 Drug Treatment; Cricetinae; Disease Models, Animal; Humans; Lactams; Leucine; Mesocricetus; Nitriles; Proline; Respiratory Mucosa; SARS-CoV-2; Vero Cells; Viral Protease Inhibitors; Virus Replication	2022
An oral SARS-CoV-2 M Science (New York, N.Y.), 2021, Dec-24, Volume: 374, Issue:6575 The worldwide outbreak of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic. Alongside vaccines, antiviral therapeutics are an important part of the healthcare response to countering the ongoing threat presented by COVID-19. Here, we report the discovery and characterization of PF-07321332, an orally bioavailable SARS-CoV-2 main protease inhibitor with in vitro pan-human coronavirus antiviral activity and excellent off-target selectivity and in vivo safety profiles. PF-07321332 has demonstrated oral activity in a mouse-adapted SARS-CoV-2 model and has achieved oral plasma concentrations exceeding the in vitro antiviral cell potency in a phase 1 clinical trial in healthy human participants. Topics: Administration, Oral; Animals; Clinical Trials, Phase I as Topic; Coronavirus; COVID-19; COVID-19 Drug Treatment; Disease Models, Animal; Drug Therapy, Combination; Humans; Lactams; Leucine; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Nitriles; Proline; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2; Viral Protease Inhibitors; Virus Replication	2021

Article

Year

The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern.

Nature communications, 2022, 02-15, Volume: 13, Issue:1

There is an urgent need for potent and selective antivirals against SARS-CoV-2. Pfizer developed PF-07321332 (PF-332), a potent inhibitor of the viral main protease (Mpro, 3CLpro) that can be dosed orally and that is in clinical development. We here report that PF-332 exerts equipotent in vitro activity against the four SARS-CoV-2 variants of concerns (VoC) and that it can completely arrest replication of the alpha variant in primary human airway epithelial cells grown at the air-liquid interface. Treatment of Syrian Golden hamsters with PF-332 (250 mg/kg, twice daily) completely protected the animals against intranasal infection with the beta (B.1.351) and delta (B.1.617.2) SARS-CoV-2 variants. Moreover, treatment of SARS-CoV-2 (B.1.617.2) infected animals with PF-332 completely prevented transmission to untreated co-housed sentinels.

Topics: A549 Cells; Administration, Oral; Animals; Chlorocebus aethiops; Coronavirus 3C Proteases; COVID-19; COVID-19 Drug Treatment; Cricetinae; Disease Models, Animal; Humans; Lactams; Leucine; Mesocricetus; Nitriles; Proline; Respiratory Mucosa; SARS-CoV-2; Vero Cells; Viral Protease Inhibitors; Virus Replication

2022

An oral SARS-CoV-2 M

Science (New York, N.Y.), 2021, Dec-24, Volume: 374, Issue:6575

The worldwide outbreak of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic. Alongside vaccines, antiviral therapeutics are an important part of the healthcare response to countering the ongoing threat presented by COVID-19. Here, we report the discovery and characterization of PF-07321332, an orally bioavailable SARS-CoV-2 main protease inhibitor with in vitro pan-human coronavirus antiviral activity and excellent off-target selectivity and in vivo safety profiles. PF-07321332 has demonstrated oral activity in a mouse-adapted SARS-CoV-2 model and has achieved oral plasma concentrations exceeding the in vitro antiviral cell potency in a phase 1 clinical trial in healthy human participants.

Topics: Administration, Oral; Animals; Clinical Trials, Phase I as Topic; Coronavirus; COVID-19; COVID-19 Drug Treatment; Disease Models, Animal; Drug Therapy, Combination; Humans; Lactams; Leucine; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Nitriles; Proline; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2; Viral Protease Inhibitors; Virus Replication

2021